article_metadata: Camillo Carrara Blerina Mataj Sara Gastoldi Piero Ruggenenti Savino Sciascia Dario Roccatello
article_metadata: 10.3389/fimmu.2024.1460317
article_metadata: Front Immunol
article_metadata: 2024 Sep 10:15:1460317.
article_metadata: c5b-9 antiphospholipid syndrome catastrophic antiphospholipid antibody syndrome (caps) complement system eculizumab kidney failure timing
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/39318635/
article_metadata: Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / therapeutic use Antiphospholipid Syndrome / drug therapy
article_metadata: Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / therapeutic use Antiphospholipid Syndrome / drug therapy Case Reports Adult Catastrophic Illness Complement Inactivating Agents / therapeutic use Complement Membrane Attack Complex / metabolism Female Humans Male Thrombotic Microangiopathies / diagnosis Thrombotic Microangiopathies / drug therapy Thrombotic Microangiopathies / etiology Treatment Outcome eculizumab Antibodies, Monoclonal, Humanized Complement Inactivating Agents Complement Membrane Attack Complex
article_metadata: PMC11419984
article_metadata: 39318635
article_metadata: Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome
article_metadata: 2024